Blocking the Ghrelin Receptor: A Potential New Approach to Treating Alcohol Dependence

What the researchers found

The review found that acylated ghrelin levels positively correlate with alcohol-induced brain responses in the ventral striatum — a key reward processing area — in both the right and left hemispheres. This suggests ghrelin signaling directly amplifies the brain's reward response to alcohol.

GHSR-1A antagonism has been shown in preclinical and early clinical studies to suppress artificial reward circuitries and promote self-control for alcohol consumption. Notably, GHSR-1A also exhibits ligand-independent constitutive activity, meaning it can activate reward pathways even without ghrelin binding — which may explain why some people experience persistent cravings.

Why it matters

Alcohol use disorder affects hundreds of millions of people globally, yet existing treatments have limited effectiveness and high relapse rates. The ghrelin system represents an entirely different therapeutic target — one that addresses the neurological reward mechanisms driving addiction rather than just managing withdrawal symptoms. If GHSR-1A antagonists prove effective in clinical trials, they could offer a fundamentally new approach to addiction medicine.

How the study worked

The authors conducted an updated narrative review of recent preclinical, clinical, and experimental data examining the ghrelin-GHSR-1A signaling pathway in the context of alcohol use disorder. They focused on functional and molecular mechanisms of central ghrelin signaling at different levels of alcohol craving.

What this study cannot tell us

This is a narrative review that synthesizes existing preclinical and clinical data without conducting new experiments. Most evidence for GHSR-1A antagonism in alcohol dependence comes from animal models, with limited human clinical data available. The complex neuro-psycho-endocrinological nature of alcohol use disorder means that targeting a single receptor pathway may have limited standalone efficacy. Translation from preclinical findings to effective human therapies remains unproven.

How to read the evidence

This is a narrative review summarizing preclinical, clinical, and experimental data. While the biological rationale is compelling and supported by multiple lines of evidence, the clinical data for GHSR-1A antagonism in alcohol dependence is still limited. The evidence supports further investigation rather than clinical application.

When this study was published

Published in 2022, this review captures the state of ghrelin-alcohol research at a time when GHSR-1A antagonism was gaining significant research attention. Clinical trials may have advanced since publication.

The bigger picture

This research sits at the intersection of peptide biology and addiction neuroscience. The ghrelin system's involvement in reward processing extends beyond alcohol — similar mechanisms have been explored for other substance use disorders and behavioral addictions. Understanding how peptide hormones modulate the brain's reward circuitry could reshape addiction treatment broadly, moving toward precision approaches that target specific neurobiological pathways rather than relying on generalized behavioral interventions.

Questions still open

• Will GHSR-1A antagonists prove safe and effective in large-scale human clinical trials for alcohol use disorder?
• Could the constitutive (ligand-independent) activity of GHSR-1A explain why some individuals are more vulnerable to alcohol cravings, and can this be targeted therapeutically?
• Would combining GHSR-1A antagonism with existing addiction treatments produce better outcomes than either approach alone?

Common questions

Read the original research

Therapeutic potential of GHSR-1A antagonism in alcohol dependence, a review.

Life sciences, 291, 120316

Citation

Gupta, Shreyasi; Mukhopadhyay, Sanchari; Mitra, Arkadeep. (2022). Therapeutic potential of GHSR-1A antagonism in alcohol dependence, a review.. Life sciences, 291, 120316. https://doi.org/10.1016/j.lfs.2022.120316